NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders.
Our mission is to extend and improve PD patients' quality of life by developing disease-modifying therapies that are designed to maximize efficacy while minimizing side effects normally associated with Parkinson treatment.
NurrOn is focused on discovering and developing innovative treatments that have the potential to improve clinical outcome in PD patients. The greatest unmet medical need in PD is to slow or prevent disease progression. Through targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, we aim to develop a paradigm changing PD treatment to improve patients' quality of life.
We believe that disease-modifying therapies will be achieved through targeting Nurr1, which we proved to be a new druggable PD target. NurrOn’s targeted therapies may act synergistically with existing PD drugs. We will pursue not only the monotherapy but also the combination approach in our clinical studies.